EU Investigates Data Use by X´s AI Chatbot

The European Union launches a probe into Elon Musk´s platform X regarding the use of personal data for Artificial Intelligence training.

Ireland´s Data Protection Commission (DPC), representing the European Union, has initiated an inquiry into the usage of personal data by Elon Musk´s social media platform X. This data is allegedly being utilized to train X´s Artificial Intelligence chatbot, Grok. The DPC is investigating the processing of personal data, specifically focusing on the posts available on the X platform which are publicly accessible across the EU.

The investigation aims to determine whether the handling of this personal data complies with the legal framework, especially concerning the training of Grok´s Large Language Models (LLMs). Last year, the DPC initiated a court case against X for violating data privacy laws, arguing that the platform´s usage of EU users´ public posts for Artificial Intelligence training breached rights and regulations. As X headquarters are in Ireland, the DPC is the primary authority overseeing its activities in Europe.

After X initially agreed to halt using this data, prompting the DPC to withdraw its case, developments in the platform´s Artificial Intelligence models have continued. The investigation now focuses on X´s adherence to the EU´s General Data Protection Regulation (GDPR), ensuring data processing´s lawfulness and transparency. The DPC´s move underscores the ongoing concern over privacy and data protection in Artificial Intelligence advancements.

56

Impact Score

Crescent library brings privacy to digital identity systems

Crescent is a cryptographic library that adds unlinkability to common digital identity formats, preventing tracking across credential uses while preserving selective disclosure. It supports JSON Web Tokens and mobile driver’s licenses without requiring issuers to change their systems.

Artificial Intelligence-powered remote drug testing removes barriers to recovery

Q2i and King’s College London are collaborating to evaluate an Artificial Intelligence-powered at-home drug testing system aimed at people recovering from opioid use disorder. The solution delivers digitally observed, clinically reliable results and pairs testing with contingency management and telehealth to reduce logistical barriers to care.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.